Loading…
Ken GriffinHeld
Citadel Advisors · Q2 2026
$137.79K
30.09K shares · 0.0% of portfolio
Whitehawk Therapeutics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -86.1% over 5Y.
today you would have $127.34▼ -87.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 8 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $2.42 | $3.15 | $2.02 | $12.83 | $24.15 | $14.70 | $9.36 | $25.50 | |
| P/S | 5.7x | 16.0x | 5.7x | 2.0x | 20.6x | 36.1x | 3.3x | — | 3.4x |
| P/B | 1.6x | 0.8x | 2.8x | 0.5x | 2.0x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SRZNSurrozen, Inc. | $22.42 | — | — | — | — | $263.51M |
| INFUInfuSystem Holdings, Inc | $13.11 | 32.8x | 4.4x | — | 15.03% | $261.11M |
| STROSutro Biopharma Inc | $15.73 | — | — | — | — | $260.82M |
| CAMPCamp4 Therapeutics Corp | $4.15 |
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Company description provided by Yahoo Finance.
| 3.7x |
| — |
| — |
| 1.2x |
| EPS | -$0.33 | -$2.36 | -$2.44 | -$2.69 | -$12.41 | -$1.76 | -$8.55 | -$4.65 |
| Profit margin | -270.04% | -288.26% | -245.13% | -270.04% | -397.69% | -786.36% | -24.84% | — | -51.58% |
| ROE | -50.36% | -15.11% | -121.37% | -62.52% | -38.21% | -80.71% | — | — | -17.72% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| -545.85% |
| $260.43M |
| NAGENiagen Bioscience, Inc. | $3.29 | 17.3x | 3.2x | — | 21.80% | $260.32M |
| ELDNEledon Pharmaceuticals, Inc. | $3.20 | — | 3.6x | — | -110.71% | $260.04M |